Bryan Yoon
Chief Operating Officer at TERNS PHARMACEUTICALS, INC.
Net worth: 571 697 $ as of 2024-03-30
Profile
Bryan Yoon is currently the COO, Secretary & General Counsel at Terns Pharmaceuticals, Inc. He previously worked as the Director at NightstaRx Ltd.
from 2018 to 2019.
From 2013 to 2017, he served as the Secretary & Senior Vice President-Legal Affairs at Intercept Pharmaceuticals, Inc. Bryan also held the position of Secretary & Chief Administrative Officer at LogicBio Therapeutics, Inc. from 2019 to 2020.
Additionally, he worked as the Secretary & General Counsel at Nightstar Therapeutics Ltd.
from 2017 to 2019.
Mr. Yoon completed his undergraduate and graduate degrees at Cornell University in 1999 and 2000 respectively.
He obtained his graduate degree from The University of Michigan Law School in 2005.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-22 | 87,149 ( 0.13% ) | 571 697 $ | 2024-03-30 |
Bryan Yoon active positions
| Companies | Position | Start |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Chief Operating Officer | 2020-10-31 |
Former positions of Bryan Yoon
| Companies | Position | End |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Chief Administrative Officer | 2020-11-05 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Director/Board Member | 2019-06-06 |
| NIGHTSTAR THERAPEUTICS PLC | General Counsel | 2019-05-31 |
| INTERCEPT PHARMACEUTICALS, INC. | General Counsel | 2017-10-31 |
Training of Bryan Yoon
| Cornell University | Graduate Degree |
| The University of Michigan Law School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Bryan Yoon
